Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
757.96-
QQQ
701.911.81%
BTC/USD
78294.061.9456%
DIA
524.340.28%
GLD
392.411.59%
TLT
81.05-

Allogene Therapeutics Inc (ALLO) Stock Price, Quote, News & History

ALLONASDAQ
Trade with Public
Trade with Public
$1.78
0.021.14%
At close: Sep 10, 5:00 PM EST
$1.80
0.042.27%
Pre-Market: 5:21 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Allogene Therapeutics (ALLO) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
-
Close
$1.78
Volume / Avg.
1.03K / 7.25M
Day Range
- - -
52 Wk Range
1.04 - 4.46
Market Cap
$621.88M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
40
Short Interest
18.93%
Days to Cover
12.15

Recent Allogene Therapeutics, Inc. News

Aehr Test Systems, CareDx, Okta And Other Big Stocks Moving Higher On Thursday

U.S. stocks were mixed on Thursday, with the Dow Jones gaining 0.1%. Aehr Test Systems shares rose 15.6% following a $41M production order from an AI customer. Other big gainers include Xanadu Quantum Tech, CareDx Inc, and Nextnav Inc.
Avi Kapoor

Dell To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday

Analysts change outlook on top names: Mizuho downgrades PYPL, B of A increases CIEN PT, Needham raises TSM PT, HC Wainwright slashes ALLO PT, Goldman raises MS PT, Baird raises WM PT, Bernstein raises INTC PT, B of A raises PNC PT.
Avi Kapoor

Nasdaq Surges 200 Points; Morgan Stanley Posts Upbeat Earnings

US stocks rise, Nasdaq up 200 points; Tech shares lead gains. Morgan Stanley beats estimates. Allbirds up 349%, Snap up 6%. Oil rises 0.7%, gold up 0.1%.
Avi Kapoor

JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnings but missing sales estimates. Other stocks also down in pre-market trading.
Avi Kapoor

Apple To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts have changed their outlook on top names. For full analyst rating changes, including upgrades/downgrades, see analyst ratings page.
Avi Kapoor

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-102.20M
Investing Cash Flow (TTM)
-131.60M
Financing Cash Flow (TTM)
220.09M
Free Cash Flow (TTM)
-102.60M
Capital Expenditure (TTM)
-402.00K
Net Change in Cash (TTM)
-13.71M

Analyst Trends and Forecast

4
3
Apr
0
0
0
0
Aug
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$352.72M
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
97.62
PB Ratio (TTM)
1.41
Earnings Yield % (TTM)
-37.08%
Earnings Yield % (FWD)
-40.17%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$1.26

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-
Total Cash
$38.63M
Debt to Equity
0.16
Issuance of Debt (TTM)
-
Repayment of Debt (TTM)
-

Key Statistics

Open
-
Close
$1.78
Volume / Avg.
1.03K / 7.25M
Day Range
- - -
52 Wk Range
1.04 - 4.46
Market Cap
$621.88M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
40
Short Interest
18.93%
Days to Cover
12.15

About

Sector
Health Care
Industry
Biotechnology
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf"...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Allogene Therapeutics (ALLO) stock?

A

You can purchase shares of Allogene Therapeutics (NASDAQ:ALLO) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Allogene Therapeutics (ALLO) competitors?

Q

What is the forecast, or price target, for Allogene Therapeutics (ALLO) stock?

A

Allogene Therapeutics has a consensus price target of $7.68.

Q

What is the current price for Allogene Therapeutics (ALLO)?

A

The stock price for Allogene Therapeutics (NASDAQ: ALLO) is $1.8 last updated September 14, 2026 at 5:20 AM EDT.

Q

Does Allogene Therapeutics (ALLO) pay a dividend?

A

There are no upcoming dividends for Allogene Therapeutics.

Q

When is Allogene Therapeutics (NASDAQ:ALLO) reporting earnings?

A

Allogene Therapeutics does not have any upcoming earnings scheduled.

Q

Is Allogene Therapeutics (ALLO) going to split?

A

There is no upcoming split for Allogene Therapeutics.

Q

What sector and industry does Allogene Therapeutics (ALLO) operate in?

A

Allogene Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved